Gabapentin Tablet, Film Coated
Product Images NDC 71335-1026
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)
Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)
Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)
This data presents information on the mean pain score for a 4-week fixed dose period. The study involved the use of Gabapentin, with a dosage of 1800 mg/day for one group and 2400 mg/day for another group. The placebo group is also mentioned. However, there is no further information on the study design or outcomes.*
Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)
This is a statistical analysis of controlled PHN studies. The data in figure 3 shows the percentage of patients who responded to treatment, with a pain score reduction of more than 50%, at the end of the study. Study 2 had a slightly higher percentage of responders at 34%, compared to Study 1 which had 32%. The text also includes some monetary values, GBP 3600, GBP 1800 and GBP 2400, likely representing costs associated with the study.*
Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)
Label (Lbl713351026)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.